On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
Opens in a new tab or window The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral ...